Stem Cell and Regenerative Medicine Consultation Selling — 60-Min Training

Direct Answer

The Compliant Regenerative Medicine Consultation Playbook is a 60-minute training for patient consultants and clinical liaisons at PRP, exosome, BMAC, and stem-cell IV practices that converts $0 consults into $5,000-$25,000 treatment packages without crossing the FDA Center for Biologics Evaluation and Research (CBER) compliance line.

Anchored on 21 CFR 1271 HCT/P guidance, the International Society for Stem Cell Research (ISSCR) Guidelines for Stem Cell Research and Clinical Translation, AAOS Clinical Practice Guidelines for PRP, and the Mayo Clinic Center for Regenerative Biotherapeutics consult model, the session drills compliant framing language, a candidacy-first screen, an evidence-based outcome conversation, a multi-option presentation that includes the "do nothing" path, and a financing-anchored ethical close using CareCredit, PatientFi, Cherry, and Prosper Healthcare Lending.

Section 1 — The Compliance Line You Cannot Cross (5 min)

Open with the regulatory reality. In Q1 2026, FDA issued warning letters to regenerative clinics in Florida, California, and Texas for marketing unapproved exosome products with disease-cure language. Zero exosome products have FDA approval for any therapeutic use as of 2026. Stem-cell SVF and most cultured-cell products remain investigational under 21 CFR 1271.

PRP and BMAC sit on firmer ground — autologous, minimally manipulated, with multiple AAOS practice statements supporting use in specific orthopedic indications.

Write the forbidden phrases on the whiteboard, then cross them out:

• "Cure" — never. The FDA enforcement record is a wall of cure-claim shutdowns.
• "FDA-approved stem-cell treatment" — false for nearly all clinic offerings; legal liability.
• "Guaranteed results" — banned under FTC advertising rules.
• "Reverses aging / regrows cartilage / repairs spinal cord" — unsupported, drives warning letters.

Replace them with the compliant frame, also on the board:

• "This is an investigational therapy. Some patients report symptom improvement. Results vary."
• "Published evidence shows [specific outcome] in [specific indication] at [specific evidence level]."
• "You are a candidate based on [criteria]. You are not a candidate if [criteria]."

Read the ISSCR 2021 Guidelines rule aloud: *"Stem cell-based interventions offered outside of clinical trials require rigorous informed consent and accurate representation of evidence."* That sentence is the consultant's north star.

Section 2 — The Candidacy-First Screen (15 min)

Most clinics lead with the price quote. Mayo Clinic Center for Regenerative Biotherapeutics leads with candidacy. So do you. The candidacy screen is the first 15 minutes of every consult — before pricing, before financing, before any treatment discussion.

Verbatim Candidacy Screen Template (consultant walks patient through, MD/DO signs at bottom):

1. Primary complaint: [Indication — knee OA, rotator cuff, plantar fasciitis, hair loss, facial aging, etc.]
2. Duration and prior treatments tried: [PT, NSAIDs, cortisone, surgery — dates]
3. Imaging on file: [MRI / X-ray / ultrasound — date and findings]
4. Exclusion conditions: Active malignancy / Active infection / Severe coagulopathy / Pregnancy / Uncontrolled diabetes / Active autoimmune flare
5. Medications: [Blood thinners, immunosuppressants, biologics — flag for MD review]
6. Realistic patient goal: Pain reduction / Function improvement / Avoid surgery / Cosmetic / Other
7. MD/DO signature confirming candidacy and consent to proceed: _______

Coach the consultants on the decline rule: declining a non-candidate is a revenue protector, not a revenue loss. A bad outcome from an off-label off-evidence treatment generates malpractice claims, state medical board complaints, and FDA scrutiny that closes the clinic.

AAOS and Mayo both teach that 15-25% of regenerative consults should result in a "not a candidate today" outcome. If your decline rate is under 10%, you are over-selling.

Have consultants role-play in pairs — one as a patient with a rotator-cuff tear who is on warfarin, one as the consultant. The consultant must catch the anticoagulant, pause, route to the MD.

Section 3 — The Evidence-Based Outcome Conversation (10 min)

The patient sat in your lobby because they read a Facebook ad. Now you walk them back to reality, without losing the relationship.

Train consultants to quote the AAOS PRP guideline language verbatim: *"PRP may be considered for symptomatic mild-to-moderate knee osteoarthritis, with moderate-strength evidence for short-term pain relief."* That is the most you can say. Anything beyond it is over-promising.

Use the NIH ClinicalTrials.gov language for stem-cell and exosome conversations: *"This is consistent with protocols currently being studied in registered trials. Outcomes from those trials are still being collected."*

What to NEVER say in the evidence conversation (read aloud, slowly):

• "You'll be back on the court in 6 weeks." — Specific outcome promise. Banned.
• "Studies show 90% of patients improve." — Cherry-picked or fabricated stat. Cite AAOS, ISSCR, ClinicalTrials.gov or stay silent.
• "This works better than surgery." — Comparative claim without head-to-head RCT. Liability.
• "Insurance doesn't cover it because it's too new — but it works." — Implies insurance is wrong. CMS non-coverage is evidence-based. Don't pick that fight.
• "Our doctor invented this protocol." — Even if true, sets up an expectation of proprietary cure. Don't.
• "If this doesn't work, you can always get surgery later." — Minimizes risk and ignores that some patients are worse candidates for surgery post-injection.

End the segment with the ethics literature quote from Dr. Leigh Turner (UC Irvine), whose published work on stem-cell clinic marketing is the most-cited ethics paper in the field: *"The widening gap between marketing claims and clinical evidence is the single largest reputational risk in regenerative medicine."* Your job is to close that gap, one consult at a time.

Section 4 — The Multi-Option Presentation and Ethical Close (10 min)

Every consult presents at least three paths — not just the most expensive one. Mayo's consult template builds this in as a hard rule.

Verbatim Multi-Option Script (consultant, after candidacy clearance):

Consultant: "Based on Dr. Patel's review of your MRI and screen, you are a candidate for treatment. I want to walk you through three paths — including doing nothing — and you tell me which fits your goals and budget."

[Patient nods. Consultant pulls up the option sheet on tablet.]

Consultant: "Path 1 — Conservative continuation. Stick with PT, NSAIDs, and the home program. Cost: minimal. Evidence: well-established. Many patients with your imaging do fine on this path for another 12-18 months."

Consultant: "Path 2 — PRP series. Three injections, 4-6 weeks apart. Total: $2,400-$3,600. Evidence: AAOS says moderate evidence for short-term pain relief in your indication. Some patients see meaningful improvement; some see none."

Consultant: "Path 3 — BMAC with PRP boost. Single procedure under ultrasound guidance. Total: $6,500-$9,500. Evidence: investigational. We have a peer-reviewed protocol but no FDA approval. Some patients in our outcomes registry report function gains; results vary."

Consultant: "I am not going to tell you which one to pick. I am going to give you the math on each, the financing options, and a 72-hour decision window. We do not pressure-close at this clinic."

[Hand patient the option sheet, walk through financing.]

Do NOT:

• Lead with the most expensive option. Lead with "do nothing," then ascend. The ethics literature is unanimous.
• Skip the 72-hour decision window. ISSCR explicitly recommends a cooling-off period for any investigational therapy consult.
• Use same-day discounts to pressure-close. The FTC has acted against clinics for this pattern. Offer a price that holds for 14 days instead.
• Quote a price without the evidence frame attached. Price-then-evidence reverses the trust order.
• Bundle exosomes into a "stem-cell package" without disclosing FDA non-approval. That is the fastest path to a warning letter on your wall.

Section 5 — The Financing Math and Honest Comebacks (15 min)

Patients balk at $8,500 cash. They sign for $165/month over 60 months. That is not a manipulation — it is a real budgeting reality. The job is to present it honestly.

The math (for a $7,500 BMAC package, mid-credit patient):

• Cash price today: $7,500
• CareCredit 24-month 0% promo: $313/month, no interest if paid in 24
• PatientFi 60-month fixed: $165/month at ~13.99% APR
• Cherry 36-month, ~80% approval rate, soft credit pull: $245/month at ~10.99% APR
• Prosper Healthcare Lending 84-month: $124/month at ~14.99% APR
• Net consultant SPIFF on closed package: typically $250-$500 plus quarterly conversion bonus

Common patient objections (rehearse the comebacks — honest, not manipulative):

• *"It's a lot of money for something not FDA-approved."* — *"You are right. This is investigational. Path 1 (conservative) is the FDA-cleanest path. If you want to try regenerative, PRP has the strongest evidence and the lowest price. We do not push Path 3 on anyone who is not comfortable with the evidence gap."*
• *"Insurance should cover this."* — *"CMS and most commercial carriers consider these investigational. I will not tell you that is wrong — they are reading the same evidence base I am. The financing options exist because the cash burden is real."*
• *"Can I think about it?"* — *"Absolutely. Our policy is a 72-hour decision window on every consult — and the price holds for 14 days. I will email you the full summary tonight."*
• *"My friend's clinic offered me the same thing for half the price."* — *"That can be real — protocols and supply chains vary. Ask them three questions: who is the medical director, what is the HCT/P sourcing, and do they have an outcomes registry. If yes to all three, they may be a great option for you. We are not going to price-match below our cost-of-care."*

The financing-first comeback is the PatientFi and Cherry training point: monthly payment + evidence-honest framing closes more packages than discount-the-cash-price ever has.

Section 6 — Commitments and Close (5 min)

Each consultant leaves with three written commitments, signed and pinned at the consult desk:

• Every consult this week gets the candidacy screen before any pricing or treatment discussion, and the MD/DO sign-off before any package is presented.
• I will present at least three options including "do nothing," and I will lead with the conservative path — never the most expensive.
• I will offer the 72-hour decision window on every package, and I will refuse to use same-day-discount pressure tactics. If a patient asks for a discount, I quote the price-holds-14-days policy instead.

Close by reading the Mayo Clinic Center for Regenerative Biotherapeutics principle aloud: *"In regenerative medicine, the integrity of the consent conversation is the integrity of the field. There is no shortcut that does not eventually shut a clinic down."*

Then route every consultant to the ISSCR Patient Handbook and have them complete the FDA CBER compliance refresher within 7 days.

FAQ

Q1: What if the patient insists on exosomes after I explain FDA non-approval? A: Document the disclosure in the chart, route to MD/DO for a second compliance conversation, and let the physician decide whether to proceed under their license. FDA warning letters in 2026 specifically target clinics where consultants sold exosomes without escalating the disclosure to a physician sign-off.

Q2: How do I handle a patient who wants stem cells for a condition with zero evidence — like Alzheimer's or autism? A: Decline. ISSCR is unambiguous: marketing stem cells for unsupported indications is the single most-cited ethics violation in Dr. Leigh Turner's published research.

Refer to ClinicalTrials.gov for any registered trials they may qualify for instead.

Q3: Is it ethical to offer SPIFFs to consultants on package closes? A: Only if the SPIFF structure also rewards decline-the-non-candidate decisions and patient satisfaction at 90 days. Pure close-rate SPIFFs create the over-selling pattern the FTC has acted against. Mayo's model pays equally on documented declines.

Q4: Can we publish patient testimonials in marketing? A: Only with explicit consent, no cure claims, and a "results vary" disclaimer. Avoid before-and-after image pairs implying outcomes are typical — that is the most-cited FTC violation pattern.

Q5: What if a competitor down the street is making cure claims and stealing my consults? A: Report the competitor to FDA MedWatch and your state medical board. Then keep doing the right thing. Compliant clinics outlast non-compliant ones; the regulatory window is narrowing every quarter.

Q6: How is this different from selling cosmetic procedures like Botox? A: Botox is FDA-approved with established outcomes. Regenerative medicine is mostly investigational with variable evidence. The consent conversation, candidacy screen, and decision window must be longer, more honest, and more conservative.

The financing math is similar; the evidence frame is the opposite.

Sources

1. FDA Center for Biologics Evaluation and Research (CBER), *Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), 21 CFR Part 1271*, fda.gov, 2024-2026.
2. FDA, *Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues*, fda.gov, updated 2026.
3. International Society for Stem Cell Research (ISSCR), *Guidelines for Stem Cell Research and Clinical Translation*, isscr.org, 2021 edition.
4. American Academy of Orthopaedic Surgeons (AAOS), *Clinical Practice Guideline on Management of Osteoarthritis of the Knee* and *PRP Position Statement*, aaos.org, 2024-2025.
5. Mayo Clinic Center for Regenerative Biotherapeutics, *Patient Consultation Model and Investigational Therapy Consent Framework*, mayo.edu, 2024-2025.
6. NIH ClinicalTrials.gov, *Registry of Active Stem Cell, PRP, and Exosome Trials*, clinicaltrials.gov, accessed 2026.
7. Leigh Turner, PhD (UC Irvine), *Direct-to-Consumer Marketing of Stem Cell Interventions: Empirical Studies and Ethical Analyses*, Cell Stem Cell and related peer-reviewed publications, 2018-2024.
8. PatientFi, Cherry, CareCredit, and Prosper Healthcare Lending, *Provider Operating Guides and Patient Financing Compliance Frameworks*, 2024-2025.